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Abstract: Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic, relapsing inflammatory
bowel diseases associated with significant morbidity. Conventional therapies for these
diseases include corticosteroids, aminosalicylates, immunomodulators, and monoclonal
antibodies. Over the years tumor necrosis factor (TNF)-α antagonists alone or in combination
with other therapies have emerged as the cornerstone of treatment for induction and
maintenance of remission of moderate to severe UC and CD. Unfortunately, some patients
with moderate to severe UC and CD are unable to attain or maintain remission with TNF-α
antagonist treatment. Vedolizumab, a humanized monoclonal antibody, is the first integrin
receptor antagonist approved that selectively antagonizes α4β7 gastrointestinal integrin
receptors. US Food and Drug Administration approval is for treatment of patients with
moderate to severe active UC and CD who have inadequate response with, lost response to, or
are intolerant to a TNF-α antagonist or an immunomodulator; or have inadequate response
with, are intolerant to, or demonstrate dependence on corticosteroids. When administered
according to approved dosing in patients with moderate to severe CD and UC, vedolizumab
induces clinical response rates up to 31.4% and 47.1% at week 6, and clinical remission
rates up to 39% and 41.8% at week 52, respectively. Serious adverse events reported with
vedolizumab include serious infections, malignancies, and anaphylaxis. Since vedolizumab is
gastrointestinal selective, to date, it has not shown evidence of causing progressive multifocal
leukoencephalopathy; however, postmarketing studies monitoring for this adverse effect are
ongoing. Further assessment of vedolizumab earlier in the course of these diseases and in
combination with other therapies is warranted.
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Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD)
are chronic, relapsing inflammatory bowel diseases (IBDs) [Lichenstein et al. 2008; Kornbluth
et al. 2010]. Differences between UC and CD
include bowel wall involvement (mucosal versus
transmural), patterns of inflammation (continuous versus noncontinuous), location of inflammation (primarily rectum and colon versus entire
gastrointestinal tract), and absence or presence of
fistulas. Common symptoms for these diseases
include diarrhea, abdominal tenderness or pain,
rectal bleeding, and possible weight loss
[Lichenstein et al. 2008; Kornbluth et al. 2010;
Cosnes et al. 2011; Danese et al. 2014]. In the
United States, the incidence and prevalence rates
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for UC and CD have been increasing and are
reported as 7.9 and 8.8 cases per 100,000 person
years and 263 and 241 per 100,000 adults diagnosed with UC and CD, respectively [Kappelman
et al. 2013; Long et al. 2014].
The exact causes of UC and CD are unknown.
Evidence suggests that environmental factors,
genetic predisposition, and changes in the gastrointestinal microbial flora may trigger an overly
aggressive immune response leading to elevations
of proinflammatory mediators [e.g. interferon γ,
certain interleukins and tumor necrosis factor α
(TNF-α)] [Abrahm and Cho, 2009]. These mediators recruit additional leukocytes, which results
in a sustained inflammatory response and tissue
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destruction [Abrahm and Cho, 2009; Zhang and
Li, 2014]. Both UC and CD can be categorized
as mild, moderate or severe, and characterized by
exacerbations and remissions in most patients
[Lichenstein et al. 2008; Kornbluth et al. 2010].
Treatment goals for patients with UC and CD
include improving symptoms, inducing and maintaining remission, and minimizing drug toxicities
[Lichenstein et al. 2008; Kornbluth et al. 2010;
D’Haens et al. 2014].
Conventional therapies for UC and CD target
various cell mediators and include corticosteroids, aminosalicylates, immunomodulators, and
monocolonal antibodies (Table 1) [Sharon et al.
1978; Horn et al. 1991; Poldosky, 2002; Rousseaux
et al. 2005; Stolfi et al. 2008; Kornbluth et al.
2010; Terdiman et al. 2013; Marinkovic et al.
2014]. Over the years, TNF-α antagonists alone
or in combination with other therapies have
emerged as the cornerstone of treatment for
induction and maintenance of remission of moderate to severe UC and CD. Unfortunately, more
than 60% of patients with UC and CD evaluated
in clinical trials were unable to attain or maintain
remission at week 52 after TNF-α antagonist
initiation [Hanauer et al. 2002; Rutgeerts et al.
2005; Colombel et al. 2007]. Moreover, it is documented that patients whose condition has failed
to respond to one TNF-α antagonist have a markedly reduced response rate when treated with a
second TNF-α antagonist [Sandborn, 2007;
Sandborn et al. 2007]. For these reasons, newer
agents are needed to treat patients with moderate
or severe UC or CD that is unresponsive, refractory, or patients who are unable to tolerate traditional treatment options.
The integrin receptor and vedolizumab
Integrin receptors have emerged as targets for
newer therapies to treat patients with IBD.
Integrins are composed of two subunits, α and β,
and are found on certain B and T lymphocytes. At
least 24 unique integrins have been identified in
various combinations of α and β subunits.
Although not exclusive, those associated with cell
migration into the gastrointestinal tissue include
α2β2, α4β1, and α4β7. By antagonizing these
receptors there is inhibition of lymphocyte migration to the gastrointestinal mucosa during the
inflammatory process [Gosh and Panaccione,
2010; Jovani and Danese, 2013]. Natalizumab,
the first integrin receptor antagonist approved by
the US Food and Drug Administration (FDA),
http://taj.sagepub.com

targets both the α4β1 and α4β7 integrins. Its initial US approval was for multiple sclerosis and
later expanded to moderate to severe CD. Though
deemed effective for CD, its use has been limited
in this patient population because it can cause
reactivation of the John Cunningham virus and
possibly cause progressive multifocal leukoencephalopathy (PML), a serious central nervous
system infection that often results in mortality
[Center for Drug Evaluation and Research, 2011;
Biogen Idec Inc., 2013].
Vedolizumab (Entyvio; Takeda Pharmaceuticals,
Deerfield, IL, USA), also known as MLN0002, is
a humanized monoclonal antibody that selectively
antagonizes α4β7 gastrointestinal integrin receptors. It was approved by the FDA in May 2014,
and is indicated for the treatment of patients with
moderate to severe active UC and CD who have
an inadequate response with, lost response to, or
are intolerant to a TNF-α antagonist or an immunomodulator; or have an inadequate response
with, are intolerant to, or demonstrate dependence on corticosteroids [Takeda Pharmaceuticals
America Inc., 2014]. Because of vedolizumab’s
receptor selectivity and improved safety profile
over natalizumab, it is considered as a new treatment option for patients with UC and CD. The
purpose of this manuscript is to review the pharmacology, pharmacokinetics, efficacy, adverse
effects (AEs), drug–drug interactions, dosage and
administration, cost, and place in therapy of
vedolizumab.
Pharmacology
Vedolizumab is a humanized, anti-α4β7 integrin,
monoclonal antibody [Takeda Pharmaceuticals
America Inc., 2014]. The α4β7 integrin is a cellsurface glycoprotein that is expressed on circulating B and T lymphocytes. It binds to adhesion
molecules on gastrointestinal and other vascular
endothelial cells to promote the influx of integrin
binds specifically to the mucosal addressin cell
adhesion molecule 1 and causes a decrease in
gastrointestinal mucosal degradation and inflammation [Erle et al. 1994; Fedyk et al. 2012].
Pharmacokinetics
Similar pharmacokinetic parameters of vedolizumab have been reported in patients with UC
and CD. In a dose-ranging study, 36 patients with
UC were administered vedolizumab as a 30–60
min intravenous infusion at doses of 2, 6, or 10
225
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Table 1. Ulcerative colitis (UC) and Crohn’s disease
(CD) therapies and proposed targets [Sharon et al.
1978; Horn et al. 1991; Poldosky 2002; Rousseaux
et al. 2005; Stolfi et al. 2008; Terdiman et al. 2013;
Marinkovic et al. 2014].
Medications

Proposed cell
mediator targets

Corticosteroids
Budesonide
Hydrocortisone
Methylprednisolone
Prednisone
Aminosalicylates
Balsalazide
Mesalamine
Olsalazine
Sulfasalazine
Immunomodulators
6-Mercaptopurine
Azathioprine
Cyclosporine
Methotrexate
TNF-α inhibitors
Adalimumab
Certolizumab pegol
Golimumab
Infliximab

COX-2, IL-1β, NFκB, IL-1β, PG

COX-2, IL-8, PPARγ, PG, leukotrienes,
NF-κB, TNF-α  
  
Chemokines, IL-8

TNF-α

COX, cyclooxygenase; IL, interleukin; NF, nuclear factor;
PG, prostaglandin; PPAR, peroxisome proliferator activated receptor; TNF, tumor necrosis factor.

mg/kg at weeks 0, 2, and 4 (induction phase) and
week 12 (maintenance phase). With each of these
doses, maximum serum concentration and area
under the curve were considered dose dependent.
Serum concentrations declined in a linear manner
when concentrations ranged from 1 to 10 μg/mL,
with a nonlinear decline thereafter. Across all
doses, the mean half-life ranged from 15–22
days [Parikh et al. 2012]. These pharmacokinetic
parameters were confirmed in phase III trials,
when 300 mg of vedolizumab was administered
as a 30 min intravenous infusion at weeks 0, 2, 6,
and then every 4 or 8 weeks thereafter to patients
with UC and CD. Trough serum concentrations
declined in a linear fashion from week 6 to week
46 from 26.3 to 11.2 μg/ml (UC) and from 27.4
to 13 μg/ml (CD), and the serum half life was
determined to be nearly 25 days. Further analysis
of these data showed a linear clearance of 0.157
L/day and a volume of distribution of approximately 5 L [Feagan et al. 2013; Sandborn et al.
226

2013; Takeda Pharmaceuticals America Inc.,
2014].
Clinical efficacy
The FDA approval of vedolizumab for UC and
CD was based on results from three prospective,
randomized, multicenter, phase III trials
(GEMINI 1, GEMINI 2, and GEMINI 3).
GEMINI 1 and 2 were integrated trials with similar study design and methodology and consisted
of both induction and maintenance studies for
UC and CD, respectively, while GEMINI 3 was
an induction only study for CD [Feagan et al.
2013; Sandborn et al. 2013; Sands et al. 2014]. In
each of these trials, patients had moderate to
severe disease (defined in Tables 2 and 3) with
treatment failure to glucocorticoids and immunomodulators (GEMINI 1, 2) or TNF-α inhibitors (GEMINI 1, 2, 3). Each of these trials is
summarized below and further detailed in Tables
2 and 3 [Feagan et al. 2013; Sandborn et al. 2013;
Sands et al. 2014].
Ulcerative colitis
GEMINI 1 evaluated the efficacy and safety of
vedolizumab for induction and maintenance in
895 adults with moderately to severely active UC
[Feagan et al. 2013]. The induction study was
divided into two cohorts. In cohort 1 patients
were randomized to intravenous vedolizumab
300 mg (n = 225) or placebo (n = 149) at weeks
0 and 2 while cohort 2 patients received openlabel vedolizumab 300 mg (n = 521) at the same
time intervals. Patients from cohorts 1 and 2 who
had a clinical response at week 6 (i.e. a 3-point or
more reduction in the Mayo Clinic score and a
30% or more reduction from the baseline score,
along with a 1-point or more decrease on the rectal bleeding subscale or a score of 0 or 1 for absolute rectal bleeding) were allowed to move into
the maintenance study. In this study patients
were randomized to one of three treatment arms:
intravenous vedolizumab 300 mg every 8 weeks,
intravenous vedolizumab 300 mg every 4 weeks,
or placebo. The primary efficacy endpoints for the
induction and maintenance studies were clinical
response at week 6 and clinical remission at
week 52, respectively. Other outcomes assessed
included durable clinical response and remission
(both at weeks 6 and 52), mucosal healing, and
corticosteroid-free remission (both at week 52).
When reporting results, all endpoint differences
were adjusted for concomitant use or no use of
http://taj.sagepub.com
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Table 2. Summary of vedolizumab phase III studies in patients with active UC.
Reference

GEMINI 1
[Feagan
et al. 2013]

Design

R, parallel
group, DB,
PC

Population

Moderate to
severe UC*
(n = 895)

Treatment

Response endpoints
Primary

Secondary

Induction
Intravenous infusion
on days 1, 15
C1R1: VDZ 300 mg
(n = 225)
C1R2: PBO (n = 149)
C2: open label VDZ
300 mg (n = 521)

Induction
Clinical response$ at
week 6
47.1% C1R1 versus
25.5% C1R2 (p <
0.001)
44.3% C2

Maintenance
R1: VDZ every 8
weeks (n = 122)
R2: VDZ every 4
weeks (n = 125)
PBO (n = 126)

Maintenance
Clinical remission‡ at
week 52
41.8% R1 and 44.8%
R2 versus 15.9% PBO
(p < 0.001 and p <
0.001, respectively)

Induction
Clinical remission‡ at week 6
16.9% C1R1 versus 5.4% C1R2
(p = 0.001)
19.2% C2
Mucosal healing§ at week 6
40.9% C1R1 versus 24.8%
C1R2 (p = 0.001)
36.7% C2
Maintenance
Mucosal healing§ at week 52
51.6% R1 and 56% R2 versus
19.8% PBO (p < 0.001 and p <
0.001, respectively)
Glucocorticoid-free remission‖
31.4% R1 and 45.2% R2 versus
13.9% PBO (p = 0.01 and p <
0.001, respectively)

*Moderate to severe active disease: baseline Mayo Clinical Score (MCS) of at least 6 points and endoscopy subscore of at least 2 points.
$Clinical response: decrease of at least 3 points in MCS and decrease of at least 30% of baseline MCS, with a decrease of at least 1 point on the
rectal bleeding subscale or a score of 0 or 1 for absolute rectal bleeding.
‡Clinical remission: MCS up to 2 points with no subscore greater than 1 point.
§Mucosal healing: score of 0 or 1 for endoscopic subscore.
‖Glucocorticoid-free remission assessed in patients receiving oral corticosteroids at baseline.
DB, double blind; C1R1, cohort 1 regimen 1; C1R2, cohort 1 regimen 2; C2, cohort 2; PBO, placebo; PC, placebo controlled, R, randomized; R1,
regimen 1; R2, regimen 2; VDZ, vedolizumab.

corticosteroids and concomitant use or prior use
of immunomodulators or TNF-α antagonists. In
the induction study, clinical response was achieved
at week 6 by 47.1% of vedolizumab-treated
patients compared with 25.5% of placebo-treated
patients [adjusted difference 21.7%, 95% confidence interval (CI) 11.6–31.7, p < 0.001, number needed to treat (NNT) = 4.6]. Other
significant differences found between cohort 1
groups at week 6 included the rate of clinical
remission [vedolizumab (16.9%) versus placebo
(5.4%); p = 0.001] and rate of mucosal healing
[vedolizumab (40.9%) versus placebo (24.8%); p
= 0.001]. For patients who received open-label
vedolizumab (cohort 2), clinical response, remission, and mucosal healing rates were 44.3%,
19.2%, and 36.7%, respectively. Of those who
moved on to the maintenance study, vedolizumabtreated patients had a better clinical remission
compared with placebo-treated patients at week
52 (every 8-week group: 41.8% versus 15.9%,
adjusted difference 26.1%; 95% CI 14.9–37.2, p
< 0.001, NNT = 3.8; and every 4-week group:
44.8% versus 15.9%, adjusted difference 29.1%;

http://taj.sagepub.com

95% CI 17.9–40.4, p < 0.001, NNT = 3.4).
Additionally, patients who received vedolizumab
every 8 weeks and every 4 weeks compared with
placebo were more likely to achieve a durable
clinical response (56.6% and 52% versus 23.8%, p
< 0.001 and p < 0.001, respectively) durable
clinical remission (20.5% and 24% versus 8.7%, p
= 0.008 and p = 0.001, respectively), mucosal
healing (51.6% and 56% versus 19.8%, p < 0.001
and p < 0.001, respectively) and corticosteroidfree remission (31.4% and 45.2% versus 13.9%, p
= 0.01 and p < 0.001) at week 52. Limitations to
this study exist. Unfortunately, the induction
study only lasted 6 weeks. Extension of the induction study would have allowed for identifying the
optimal time to induction instead of limiting it to
the 6-week time period. Likewise, the minimal
effective dose regimen was not determined since
both regimens, though not directly compared,
had similar efficacy. Finally, by using a placebo
instead of an active comparator the exact placement of vedolizumab in the treatment algorithm
for the management of moderate to severe active
UC is unknown.
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Table 3. Summary of vedolizumab phase III studies in patients with active Crohn’s disease (CD).
Reference

Design

Population

Treatment

Response endpoints
Primary

GEMINI 2
[Sandborn
et al. 2013]

R, parallel
group, DB,
PC

Moderate to
severe CD*
(n = 1115)

Induction
Intravenous infusion
on weeks 0, 2
C1R1: VDZ 300 mg (n
= 220)
C1R2: PBO (n = 148)
C2: open label VDZ
300 mg (n = 747)

Maintenance
R1: VDZ every 8
weeks (n = 154)
R2: VDZ every 4
weeks (n = 154)
PBO (n = 153)

GEMINI
3 [Sands
et al. 2014]

R, DB, PC

Moderate to
severe CD*
(n = 416)

Intravenous infusion
on weeks 0, 2, 6
VDZ 300 mg (n = 209)
PBO (n = 207)

Induction
Clinical remission† at
week 6
14.5% C1R1 vs. 6.8%
C1R2, p = 0.02
17.7% C2
CDAI-100 response‡
at week 6
31.4% C1R1 vs. 25.7%
C1R2, p = 0.23
34.4% C2
Maintenance
Clinical remission$ at
week 52
39% R1 and 36.4% R2
versus 21.6% PBO
17.4, p < 0.001 and
14.8, p = 0.004,
respectively

TNF-α antagonist
failure population
Clinical remission$ at
week 6
15.2% VDZ versus
12.1% PBO
3.0 (95% CI −4.5 to
10.5), p = 0.433

Secondary

Maintenance
CDAI-100 response‡ at
week 52
43.5% R1 and 45.5% R2 versus
30.1% PBO
13.4, p = 0.01 and
15.4, p = 0.005, respectively
Glucocorticoid-free remission§
31.7% R1 and 28.8% R2 versus
15.9% PBO
15.8, p = 0.02 and
12.9, p = 0.04, respectively
TNF-α antagonist failure
population
CDAI-100 response‡ at week 6
39.2% VDZ versus 22.3% PBO
16.9 (95% CI 6.7–27.1), p = 0.001
Clinical remission$ at week 10
26.6% VDZ versus 12.1% PBO
14.4 (95% CI 5.7–23.1), p = 0.001
Overall population
Clinical remission† at week 6
19.1% VDZ versus 12.1% PBO
6.9 (95% CI 0.1–13.8), p = 0.048
Clinical remission$ at week 10
28.7% VDZ versus 13.0% PBO
15.5 (95% CI 7.8–23.3), p < 0.0001

*Moderate to severe active disease: CD Activity Index (CDAI) score of 220–450.
$Clinical remission: CDAI score up to 150 points.
‡CDAI-100 response: decrease of at least 100 points in CDAI score.
§Glucocorticoid-free remission: clinical remission without corticosteroids at week 52.
C1R1, cohort 1 regimen 1; C1R2, cohort 1 regimen 2; C2, cohort 2; CI, confidence interval; DB, double blind; PBO, placebo; PC, placebo controlled;
R, randomized; R1, regimen 1; R2, regimen 2; VDZ, vedolizumab.

Crohn’s disease
GEMINI 2 assessed the efficacy and safety of
vedolizumab for induction and maintenance in
1115 adults with moderate to severe active CD
[Sandborn et al. 2013]. Similar to GEMINI 1, the
induction study consisted of two cohorts. In
cohort 1 patients were randomized to intravenous
vedolizumab 300 mg (n = 220) or placebo (n =
148) at weeks 0 and 2 while patients in cohort 2
228

received open-label vedolizumab 300 mg (n =
747) also at weeks 0 and 2. All patients from
cohorts 1 and 2 moved onto the maintenance
phase and were followed through week 52, yet
they were divided into two groups based on clinical response [i.e. ⩾70-point reduction in the CD
Activity Index (CDAI) at week 6]. Patients who
were considered ‘clinical responders’ were randomized equally to vedolizumab 300 mg every 8
http://taj.sagepub.com
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weeks, vedolizumab 300 mg every 4 weeks, or placebo, while those who were considered ‘clinical
nonresponders’ received vedolizumab 300 mg
every 4 weeks. The primary efficacy outcomes
for these studies were clinical remission (CDAI
score ⩽ 150 points) and CDAI-100 response
(⩾100-point decrease in the CDAI score) at
week 6 (induction) and clinical remission at
week 52 (maintenance). Secondary outcomes
measured at week 6 for the induction study were
a change in mean C-reactive protein levels from
baseline and at week 52 for the maintenance
study, a CDAI-100 response, glucocorticoidfree remission (i.e. no corticosteroid at week 52
use while in clinical remission), and durable
clinical remission (i.e. clinical remission at 80%
or more of study visits that included the final
visit). In cohort 1 of the induction study, more
patients receiving vedolizumab treatment
achieved clinical remission at week 6 compared
with patients receiving placebo (14.5% versus
6.8%, p = 0.02, respectively). However, no
significant difference in CDAI-100 response
[vedolizumab (31.4%) versus placebo (25.7%);
p = 0.23] or changes in mean C-reactive protein
levels from baseline were detected at week 6. Of
the patients in cohort 2, 17.7% (132/747)
achieved clinical remission and 34.4% (257/747)
had a CDAI-100 response at week 6. In the
maintenance study, a greater percentage of
patients who received vedolizumab achieved
clinical remission at week 52 [every 8 weeks
(39.0%), every 4 weeks (36.4%) compared with
placebo (21.6%), p < 0.001 and p = 0.004,
respectively]. Additionally, when patients who
received vedolizumab treatment were compared
with those receiving placebo there was a significant difference between groups for CDAI-100
response [every 8 weeks (43.5%), every 4 weeks
(45.5%), placebo (30.1%); p = 0.01 and p =
0.005, respectively] and glucocorticoid-free
remission [every 8 weeks (31.7%), every 4 weeks
(28.8%), placebo (15.9%), p = 0.02 and p =
0.04, respectively]. There was no difference
between groups for durable clinical remission.
This study may be limited by its study population. The majority of enrolled patients had
extremely refractory and complicated disease
with nearly half of patients having a history of
surgery or fistulizing disease and 15% of patients
having active, draining fistulas at enrollment.
This population has not been included in previous trials with TNF-α inhibitors and may have
confounded the response rates reported for
vedolizumab.
http://taj.sagepub.com

In an effort to examine subpopulations that may
benefit from vedolizumab therapy in active
CD, the GEMINI 3 study was conducted to
determine the efficacy of vedolizumab induction
specifically in those with moderately or severely
active CD whose condition previously failed to
respond to TNF-α antagonists [Sands et al.
2014]. Patients were randomized to receive
intravenous vedolizumab 300 mg (n = 209) or
placebo (n = 207) at weeks 0, 2, and 6.
Randomization was stratified based on previous
TNF-α antagonist status, concomitant corticosteroid use, and concomitant immunosuppressive
use. The majority of patients (76%, 315/416)
had disease that failed to respond to previous
TNF-α antagonist therapy and this was considered the primary efficacy analysis population.
The primary efficacy outcome was clinical
remission (CDAI ⩽ 150 points) at week 6 in
patients whose condition failed to respond to
prior TNF-α antagonist treatment. Secondary
efficacy outcomes for the TNF-α antagonist failure population included CDAI-100 response
(⩾100-point decrease from baseline in CDAI) at
week 6 and clinical remission at week 10 and for
the overall population included clinical remission at weeks 6 and 10. There was no significant
difference between treatment groups for the proportion of patients achieving clinical remission
at week 6 [vedolizumab (15.2%) versus placebo
(12.1%); p = 0.433]. Since the primary outcome
was not statistically significant, analysis of
secondary outcomes was only completed for characterization purposes. In the TNF-α antagonistfailure population, patients who received
vedolizumab treatment had a greater CDAI-100
response compared with placebo at week 6
(39.2% versus 22.3%, p = 0.001) and clinical
remission was achieved in more patients treated
with vedolizumab at week 10 compared with
those receiving placebo (26.6% versus 12.1%,
p = 0.001). In the overall population, a greater
proportion of patients who received vedolizumab
achieved clinical remission at week 6 [vedolizumab (19.1%) versus placebo (12.1%); p =
0.048] and at week 10 [vedolizumab (28.7%)
versus placebo (13.0%); p < 0.0001]. Despite
the insignificant results of the primary efficacy
outcome, the authors state that the collective
primary and secondary results suggest that the
full effects of vedolizumab on clinical remission
may not be realized until after week 6 of treatment, specifically in patients whose condition
failed to respond to prior TNF-α antagonist
therapy.
229
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Other clinical trials evaluating vedolizumab in
adults with moderate or severe active UC or CD
are ongoing. Two of these trials are designed to
assess clinical response and clinical remission at
longer time periods than the previously published
trials (i.e. induction therapy at week 10 and maintenance at week 60). One trial (GEMINI LTS)
is focusing on long-term safety (i.e. up to 7
years) and another trial is evaluating vedolizumab
when administered as a subcutaneous injection
[ClinicalTrials.gov identifiers: NCT00790933,
NCT02038920, NCT02039505, NCT0216342].
Adverse effects
Vedolizumab is generally well tolerated with an
AE profile and tolerability being relatively similar
among trials. AEs reported in 10% or more of
patients receiving vedolizumab in these trials
include upper respiratory infection, nasopharyngitis, abdominal pain, nausea, CD exacerbation,
arthralgia, pyrexia, and headache [Feagan et al.
2013; Sandborn et al. 2013; Sands et al. 2014]. In
the GEMINI 1 study, the incidence of serious AEs
did not differ from placebo (12.4% versus 13.5%,
respectively); however, in GEMINI 2, there was a
higher incidence of serious infections and malignancies reported in patients receiving vedolizumab
compared with those on placebo (serious infections: 5.5% versus 3.0%, respectively; and malignancies: 0.5% versus 0.3%, respectively) [Feagan
et al. 2013; Sandborn et al. 2013; Takeda
Pharmaceuticals America Inc., 2014]. Infusionrelated reactions (up to 4% of patients) have been
reported with vedolizumab administration. The
most common infusion-related reaction symptoms include nausea, headache, pruritus, dizziness, fatigue, pyrexia, urticaria, and vomiting.
Anaphylaxis has rarely (i.e. one patient in clinical
trials) been reported with vedolizumab [Takeda
Pharmaceuticals America Inc., 2014].
PML
More than 3000 patients received vedolizumab in
clinical studies for a median of 313 days with no
cases of PML reported [ClinicalTrials.gov identifier: NCT00790933; Feagan et al. 2013; Sandborn
et al. 2013; Sands et al. 2014]. Prior to FDA
approval, an independent adjudication committee
of the FDA conducted a risk assessment and minimization for the association of PML with vedolizumab and no cases of PML were identified
[FDA, 2013]. Thus, vedolizumab was FDA
approved without a risk evaluation minimization
230

strategy. However, to ensure patient safety, the
manufacturer of vedolizumab must conduct a
prospective, observational cohort study that compares vedolizumab with other treatments for IBD
with a primary outcome of serious infections and
secondary outcomes including PML. The
expected completion date for the study is 2021
[Gingery, 2014]. Additionally, an open-label
phase III trial to determine the long-term safety
of vedolizumab in patients with UC and CD
(GEMINI LTS), with safety evaluations including PML, is ongoing and due to be completed in
March 2016 [ClinicalTrials.gov identifier:
NCT00790933].
Immunogenicity
An early formulation of vedolizumab (MLN002)
was derived from mouse myeloma cell lines and
caused human anti-human antibodies (HAHA)
development in up to 44% of patients [Feagan
et al. 2005; Parikh et al. 2012]. In an effort to
reduce immunogenicity, a new formulation of
vedolizumab derived from a Chinese hamster
ovary cell based system was developed [Parikh
et al. 2012]. This new formulation was evaluated
in the GEMINI 1, 2, and 3 studies and resulted
in 1–4.1% of patients being positive for antivedolizumab antibodies at any time point and
0.4–1% of patients being persistently positive
throughout the trials [Feagan et al. 2013; Sandborn
et al. 2013; Sands et al. 2014].
Drug–drug interactions
Concomitant administration of vedolizumab with
TNF-α antagonists and natalizumab should be
avoided because of increased infection risk and
PML, respectively. Additionally, live vaccines
should only be given to patients receiving vedolizumab if the benefit clearly outweighs the risk
[Takeda Pharmaceuticals America Inc., 2014].
Dosing and administration
Before starting vedolizumab therapy, patients
should be considered for tuberculosis screening,
have baseline liver enzyme tests drawn, and
brought up to date with all routine vaccinations.
If vaccinations need to be given while a patient is
receiving vedolizumab then inactivated vaccines
may be given when indicated (though lower seroconversion rates may or may not occur), yet live
vaccines should only be given after risk–benefit
considerations. To date, no reports of secondary
http://taj.sagepub.com
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transmission of infection by live vaccines in
patients receiving vedolizumab exist [Takeda
Pharmaceuticals America Inc., 2014].
Initial dose-finding studies for vedolizumab used
weight-based dosing with doses ranging from
0.15 to 10 mg/kg administered as single doses or
at different dosing intervals (e.g. weeks 0 and 4 or
weeks 0, 2, 4, and 12) [Feagan et al. 2000, 2005,
2008; Parikh et al. 2012]. In phase III trials,
vedolizumab dosing was standardized to a 300
mg intravenous infusion given at weeks 0, 2, for
induction and then every 4 or 8 weeks for maintenance. This standardized dose corresponded to a
mean dose of 4.1 mg/kg (UC) and 4.3 mg/kg
(CD), with induction primarily achieved by week
6 and similar clinical outcomes when maintenance doses were given every 4 or 8 weeks [Feagan
et al. 2013; Sandborn et al. 2013]. These results
led to the FDA-approved dosing regimen of 300
mg as a 30 min intravenous infusion on weeks 0,
2, and 6, and then every 8 weeks thereafter for
both UC and CD [Takeda Pharmaceuticals
America Inc., 2014]. Product labeling recommends that vedolizumab treatment be discontinued if patients do not show signs of response by
week 14 [Takeda Pharmaceuticals America Inc.,
2014].
Due to the risk of hypersensitivity reactions,
including anaphylaxis, vedolizumab must be
administered by a healthcare provider equipped
to respond to such reactions. Additionally,
patients must be monitored for these possible
infusion-type reactions throughout the 30 min
infusion period [Takeda Pharmaceuticals America
Inc., 2014]. If patients have a non-life-threatening
infusion reaction history then administration of
acetaminophen, antihistamines, or corticosteroids should be considered before the start of the
infusion [Takeda Pharmaceuticals America Inc.,
2014]. However, if a serious hypersensitivity
reaction occurs during vedolizumab administration, vedolizumab should be immediately discontinued and medications for treating the reaction
administered to the patient (e.g. epinephrine,
antihistamines, corticosteroids).
Cost considerations
The average wholesale cost of a 300 mg vial of
vedolizumab in the US is $5782.80 [The Redbook
(On Line), 2014]. Based on the recommended
dosing of 300 mg on weeks 0, 2, 6, and then every
8 weeks thereafter, the cost of vedolizumab for the
http://taj.sagepub.com

initial year of treatment is approximately $52,000
and for subsequent years approximately $34,700.
To account for individual drug reimbursement,
vedolizumab should generally be administered in
an outpatient infusion clinic setting. The manufacturer of vedolizumab does provide support for
copayment assistance for those with private insurance, identification of independent patient support foundations for possible financial assistance
for those with Medicare/Medicaid, and determination of patient assistance qualification for those
without insurance [Entyvio Connect, 2015]. To
date, cost-effectiveness analyses comparing vedolizumab with other therapies approved for UC
and CD have not been performed.
Conclusion
Vedolizumab is an α4β7 integrin antagonist
approved for use in patients with moderate to
severe UC or CD who are considered nonresponders, have relapsing disease, or are unable
to tolerate TNF-α antagonists or who or have an
inadequate response with, are intolerant to, or
demonstrate dependence on corticosteroids.
When administered according to approved dosing
in patient with moderate to severe CD and UC,
vedolizumab induces clinical response rates up to
31.4% and 47.1% at week 6 and clinical remission rates at week 52 up to 39% and 41.8%.
Unlike other FDA approved integrin antagonists,
vedolizumab is gastrointestinal selective and has
not shown evidence of causing PML; however,
postmarketing studies are ongoing to ensure
patient safety for this serious AE. Other serious
AEs reported in trials with vedolizumab include
serious infections, malignancies, and anaphylaxis.
Further assessment of vedolizumab earlier in the
course of these diseases and in combination with
other therapies is warranted.
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